文献速递肿瘤 PET/CT核素与放射性配体治疗

同源重组修复基因改变与新诊断激素敏感性前列腺癌且传统影像学定义远处转移灶≤5个患者中更多前列腺特异性膜抗原阳性转移灶强相关

Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-16

这项多中心回顾性研究纳入1214例新诊断激素敏感性前列腺癌且传统影像学定义远处转移灶≤5个的患者,全部接受PSMA PET/CT、传统影像学和循环肿瘤DNA检测19个HRR基因。结果显示BRCA突变携带者与其他HRR基因突变者PSMA PET/CT检出率高于传统影像学的比例相似(43.6% vs 39.3%,p=0.554),但均显著高于无突变者(20.5%,p=0.00001);接受根治性前列腺切除术的无PSMA阳性远处病灶非转移患者中,无HRR基因突变者PSA应答率显著高于HRR基因突变者(96.9% vs 90.2%,p=0.003)。

要点

  • BRCA突变者与其他HRR突变者PSMA PET/CT检出率高于传统影像学的比例相似(43.6% vs 39.3%,p=0.554)。
  • BRCA突变者和其他HRR突变者该比例均显著高于无突变者(20.5%,p=0.00001)。
  • 接受根治性前列腺切除术的无PSMA阳性远处病灶非转移患者中,无HRR突变者PSA应答率显著高于HRR突变者(96.9% vs 90.2%,p=0.003)。

核心结论

  • HRR基因改变与新诊断激素敏感性前列腺癌且传统影像学定义远处转移灶≤5个患者中更多PSMA阳性转移灶显著相关,并与接受根治性前列腺切除术的非转移患者更差结局相关。

研究设计与样本

  • 多中心回顾性研究纳入1214例新诊断激素敏感性前列腺癌且传统影像学定义远处转移灶≤5个的患者,全部接受PSMA PET/CT、传统影像学和循环肿瘤DNA检测19个HRR基因。

主要发现

  • 骨转移检出率比较中,BRCA突变携带者PSMA PET/CT检出率高于传统影像学的比例为43.6%,其他HRR基因突变者为39.3%(p=0.554),无突变者为20.5%(p=0.00001)。
  • 远处淋巴结和区域淋巴结转移检出率分析观察到相似结果。
  • 接受根治性前列腺切除术的无PSMA阳性远处病灶非转移患者中,无HRR基因突变者PSA应答率为96.9%,HRR基因突变者为90.2%(p=0.003)。

关键数值与推荐

  • PSA应答定义为6个月后达到PSA水平<0.1 ng/ml。
  • 中位PSA水平为22.7 ng/ml。

临床怎么用

  • 作者认为HRR基因状态应被视为在设计涉及SBRT的临床试验和制定影像策略时推荐PSMA PET/CT的潜在指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The differences in imaging between prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and conventional imaging (CI) significantly impact disease staging, subsequently influencing the scope and clinical efficacy of stereotactic body radiotherapy (SBRT). In this multicenter retrospective study, we aimed to explore the effect of homologous recombination repair (HRR) gene status on the imaging differences between PSMA PET/CT and CI, which may have important implications for treatment selection. PATIENTS AND METHODS: A total of 1214 newly diagnosed hormone-sensitive prostate cancer (HSPC) patients with ≤ 5 CI-defined distant metastatic lesions were included. All patients underwent PSMA PET/CT, CI, and circulating tumor DNA testing for 19 HRR genes. The PSA response was defined as achieving a PSA level of < 0.1 ng/ml after 6 months. RESULTS: The median PSA level was 22.7 ng/ml. In the comparison of bone metastasis detection rates, the proportion of patients with higher detection rates on PSMA PET/CT than on CI was similar between BRCA mutation carriers and those with other HRR gene mutations (43.6% vs. 39.3%, p = 0.554), yet significantly higher in both groups compared to non-mutation carriers (20.5%, p = 0.00001). Similar results were observed in the analysis of metastasis detection rates for distant lymph nodes and regional lymph nodes. In non-metastatic HSPC patients without PSMA-positive distant disease who accepted radical prostatectomy (RP), patients without HRR gene mutations exhibited a significantly higher PSA response rate compared to HRR gene mutated patients (96.9% vs. 90.2%, p = 0.003). CONCLUSIONS: HRR gene alterations were significantly associated with a higher number of PSMA-positive metastases in newly diagnosed HSPC with ≤ 5 CI-defined distant metastases and worse outcomes in non-metastatic HSPC accepting RP. This finding suggests that HRR gene status should be considered as a potential indicator for recommending PSMA PET/CT in the design of clinical trials involving SBRT and in shaping imaging strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pan J, Zhu B, Wu J, et al. Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases. Eur J Nucl Med Mol Imaging. 2025. PMID: 40237795. doi:10.1007/s00259-025-07278-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。